Peter Wehrwein, Managing Editor

Raphael J. Landovitz, M.D., of UCLA, says HIV prevention science has surged ahead of the world's ability to deliver it.

Raphael J. Landovitz, M.D., says rare lenacapavir breakthrough infections raise new questions about how often patients need testing between PrEP doses.

Raphael J. Landovitz, M.D., of UCLA says surveillance gaps, Medicaid nonexpansion states and injectable pricing are stalling U.S. PrEP uptake.

Monica Gandhi, M.D., M.P.H., of UCSF, told AIDS 2026 that five years after approval, long-acting HIV drugs remain largely confined to wealthy countries.

Zambia's director of infectious disease spoke about the pared-down "basic minimum package" now adopted in Malawi, Mozambique and Kenya as U.S. funding for HIV response tightened.

Researchers report positive results from open-label extension studies amid looming concerns that the long-acting injectable won’t be available where it is needed.

Disbursements for the HIV response dropped by 25% from 2024 to 2025

A once-weekly oral HIV treatment could make a major difference in resource-constrained settings, says the executive director of AVAC.

People are beginning to fall out of treatment because of the PEPFAR funding cuts but the infrastructure of the programs has survived, says the executive director off AVAC, a U.S. organization that advocates for HIV prevention.

AVAC Executive Director Mitchell Warren says HIV prevention science has never been stronger, even as funding cuts have left program infrastructure badly weakened.

Renee Heffron, Ph.D., M.P.H., of the University of Alabama at Birmingham, says the HIV field has found new collaborations and funders after major disruptions in U.S. funding and cannot afford to lose ground on prevention.

Zambia has received just 13,000 of the tens of thousands of lenacapavir doses it hopes to get for PrEP, forcing rationing, says Lloyd Mulenga, M.B.Ch.B., Ph.D., a top health official in Zambia.

Zambia's Lloyd Mulenga, M.B.Ch.B., Ph.D., says U.S. funding cuts have imperiled HIV prevention programs in his country even as treatment and lab support continue.

Mulenga, a top health official in Zambia, says the country cut new HIV infections from 58,000 to 28,000 a year, but U.S. funding cuts and disruption threaten those gains, especially among young women.

A monthly pre-exposure prophylaxis (PrEP) pill would be less burdensome than daily pills and would be an important addition to the choices for HIV prevention, says Heffron, an HIV/AIDS researcher at the University of Alabama at Birmingham who is co-chairing a preconference meeting on HIV prevention today before the official start of the International AIDS Society meeting tomorrow in Rio de Janeiro, Brazil.

Renee Heffron, Ph.D., M.P.H., of the University of Alabama at Birmingham, discusses PrEP choice and alternative ways of delivery HIV prevention as she previews a preconference meeting, "HIV prevention, science and access" scheduled for today that she is co-chairing.

Industry leaders Tom Kraus and Shawn Gremminger debated 340B’s value during a Managed Healthcare Executive/Drug Topics webinar. Panelists clashed over transparency, safety-net eligibility, and how 340B savings should be spent.

Survey of PEPFAR-funded organizations shows the effects of the administration's policies.

Research suggests that uveitis could be a clinical marker for the cancer-targeted immune response that Keytruda and other immune checkpoint inhibitors are designed to produce.

The anti-inflammatory effects of statins may explain the lower risk of proliferative vitreoretinopathy.

On a state-by-state basis, Nebraska had the highest rate and New Jersey, the lowest, according to data presented today.

Results of a real-world evidence study show 40% nonpersistence after a year and 80% by year 7.

Disruption in copay assistance may be one of the reasons.

Experts agreed that staging and surveillance imaging should be used when there is a 15% risk of metastasis.

Transparency Rising is the new name for Transparency-Rx, a trade group of smaller PBMs challenging the "big 3."

University of Vermont Health dermatologists argue that is wasteful and causes undue worry to routinely test patients taking isotretinion for elevated liver enzymes and triglycerides.

The findings from a matched cohort study add to the body of evidence that people with vitiligo are likely to contend with other health problems.

There are lots of clues. But far more research is needed to find out whether metabolic dysfunction-associated steatotic liver disease (MASLD) plays a causative role in breast cancer.

Results from the DAPHNe trial point to ctDNA as having a role in guiding treatment, but the researchers and a commentator say more research needs to be done before determining exactly what it is.

Kutscher says MDVIP is expanding into specialty care and eyeing pediatrics.